hrcak mascot   Srce   HID

Ostalo

TEN YEARS AFTER PUBLISHING RESULTSFROM THE HEART OUTCOMES PREVENTION EVALUATION STUDY – HOPE:IMPLICATIONS ON TREATMENT WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORSIN CLINICAL PRACTICE

Darko Počanić

Puni tekst: hrvatski, pdf (185 KB) str. 0-0 preuzimanja: 53* citiraj
APA 6th Edition
Počanić, D. (2011). DESET GODINA OD OBJAVE ISPITIVANJATHE HEART OUTCOMES PREVENTION EVALUATION STUDY – HOPE: ZNAČENJE REZULTATA NA PRIMJENU INHIBITORAANGIOTENZIN-KONVERTIRAJUĆEG ENZIMA U KLINIČKOJ PRAKSI. Liječnički vjesnik, 133 (1-2), 0-0. Preuzeto s https://hrcak.srce.hr/171657
MLA 8th Edition
Počanić, Darko. "DESET GODINA OD OBJAVE ISPITIVANJATHE HEART OUTCOMES PREVENTION EVALUATION STUDY – HOPE: ZNAČENJE REZULTATA NA PRIMJENU INHIBITORAANGIOTENZIN-KONVERTIRAJUĆEG ENZIMA U KLINIČKOJ PRAKSI." Liječnički vjesnik, vol. 133, br. 1-2, 2011, str. 0-0. https://hrcak.srce.hr/171657. Citirano 19.10.2019.
Chicago 17th Edition
Počanić, Darko. "DESET GODINA OD OBJAVE ISPITIVANJATHE HEART OUTCOMES PREVENTION EVALUATION STUDY – HOPE: ZNAČENJE REZULTATA NA PRIMJENU INHIBITORAANGIOTENZIN-KONVERTIRAJUĆEG ENZIMA U KLINIČKOJ PRAKSI." Liječnički vjesnik 133, br. 1-2 (2011): 0-0. https://hrcak.srce.hr/171657
Harvard
Počanić, D. (2011). 'DESET GODINA OD OBJAVE ISPITIVANJATHE HEART OUTCOMES PREVENTION EVALUATION STUDY – HOPE: ZNAČENJE REZULTATA NA PRIMJENU INHIBITORAANGIOTENZIN-KONVERTIRAJUĆEG ENZIMA U KLINIČKOJ PRAKSI', Liječnički vjesnik, 133(1-2), str. 0-0. Preuzeto s: https://hrcak.srce.hr/171657 (Datum pristupa: 19.10.2019.)
Vancouver
Počanić D. DESET GODINA OD OBJAVE ISPITIVANJATHE HEART OUTCOMES PREVENTION EVALUATION STUDY – HOPE: ZNAČENJE REZULTATA NA PRIMJENU INHIBITORAANGIOTENZIN-KONVERTIRAJUĆEG ENZIMA U KLINIČKOJ PRAKSI. Liječnički vjesnik [Internet]. 2011 [pristupljeno 19.10.2019.];133(1-2):0-0. Dostupno na: https://hrcak.srce.hr/171657
IEEE
D. Počanić, "DESET GODINA OD OBJAVE ISPITIVANJATHE HEART OUTCOMES PREVENTION EVALUATION STUDY – HOPE: ZNAČENJE REZULTATA NA PRIMJENU INHIBITORAANGIOTENZIN-KONVERTIRAJUĆEG ENZIMA U KLINIČKOJ PRAKSI", Liječnički vjesnik, vol.133, br. 1-2, str. 0-0, 2011. [Online]. Dostupno na: https://hrcak.srce.hr/171657. [Citirano: 19.10.2019.]

Sažetak
Ten years ago results from The Heart Outcomes Prevention Evaluation Study were published. Those results had
a great impact on position of ACE inhibitors in clinical practice. In the study, comparsion of ramipril in daily dosage up to
10 mg and placebo in 9541 patients with high cardiovascular risk during 4.5 years of follow-up resulted in relative risk
reduction for all primary end-points: cardiovascular mortality, myocardial infarction and stroke for 22% in patients treated
with ramipril. Systolic blood pressure was reduced minimally for 3 mmHg. The effect was indipendent of age, gender,
concomitant diseases or therapy. Extended follow-up of the patients for further 2.6 years showed prolonged beneficial effect
of ramipril. Ramipril reduced relative risk for newly developed diabetes for 34%. Results of the study greatly influenced
the guidelines for treatment of patients with cardiovascular diseases. This study proved benefits of ACE inhibitors in primary
prevention in patients with high cardiovascular risk

Ključne riječi
Angiotensin-converting enzyme inhibitors – therapeutic use; Ramipril – therapeutic use; Cardiovascular diseases – drug therapy, mortality, prevention and control; Myocardial infarction – mortality, prevention and control; Stroke – mortality, prevention and control; Diabetes complications – prevention and control

Hrčak ID: 171657

URI
https://hrcak.srce.hr/171657

[hrvatski]

Posjeta: 100 *